Anlotinib Plus Penpulimab for the Treatment of Sensitive Relapsed Small-Cell Lung Cancer
Status:
Recruiting
Trial end date:
2023-12-31
Target enrollment:
Participant gender:
Summary
Anlotinib is a multi-target receptor tyrosine kinase inhibitor in domestic research and
development. It can inhibit the angiogenesis related kinase, such as VEGFR, FGFR, PDGFR, and
tumor cell proliferation related kinase -c-Kit kinase. In the phase II ALTER1202 trial,
patients who failed at least two kinds of systemic chemotherapy regimens (third line or
beyond) or drug intolerance were treated with anlotinib or placebo, the anlotinib group PFS
and OS were 4.1 months and 7.3 months, the placebo group PFS and OS were 0.7 months and 4.9
months. Therefore, the combination of Anlotinib and Penpulimab (a new PD-1 inhibitor) is
attempted for the treatment of sensitive relapsed small-cell lung cancer patients who were
failure in the first-line treatment of chemotherapy with platinum containing drugs, to
further improve the patient's PFS or OS.
Phase:
Phase 2
Details
Lead Sponsor:
Hunan Cancer Hospital
Collaborators:
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Fuzhou Pulmonary Hospital of Fujian